ReviewInternational journal of nanomedicine2026
Osteosarcoma Nanomedicine: From Resistance Reversal to Bone Reconstruction.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical management of Osteosarcoma (OS) is primarily hindered by two major challenges: intractable multidrug resistance and the reconstruction of critical-sized post-surgical bone defects. Nanomedicine provides a promising paradigm to overcome these clinical limitations. Synthesizing over 100 pivotal studies published predominantly between 2021 and 2026, this review moves beyond treating OS nanotherapy and bone tissue engineering as independent fields, conceptualizing them instead as a contiguous clinical pipeline. We map the trajectory of nanoscale interventions based on OS-specific biological barriers: progressing from systemic targeted nanotherapies designed to dismantle multidrug resistance and metabolic vulnerabilities (eg, ferroptosis, cuproptosis), to the localized management of the post-resection defect. Concurrently, we highlight the evolution of skeletal reconstruction through 3D-printed, stimuli-responsive biomimetic scaffolds. These smart implants exploit the unique OS microenvironment to precisely synchronize the eradication of residual microscopic disease with osteoinductive tissue regeneration. However, unpredictable in vivo degradation and chronic toxicity remain critical translational bottlenecks. Future breakthroughs demand artificial intelligence-guided predictive design and a paradigm shift from pure cytotoxicity toward immunomodulatory architectures that facilitate host-driven tumor clearance and bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.